Zanubrutinib demonstrated a non-significant improvement in response rate and lower rates of several adverse events compared with ibrutinib in patients with Waldenström macroglobulinaemia (WM).
In the phase 3 ASPEN trial, presented by Prof. Meletios Dimopoulos (University of Athens, Greece), treatment with the two Bruton's tyrosine kinase (BTK) inhibitors, zanubrutinib and ibrutinib, was compared head-to-head in patients with WM . Zanubrutinib has greater selectivity for BTK inhibition when compared with ibrutinib, which has off-target effects on expression of EGFR, FGR, FRK, HER2, HER4, ITK, JAK 3, LCK and TEC, which, for example, are thought to exacerbate diarrhoea, thrombocytopenia, bleeding, atrial fibrillation, rash and fatigue .
ASPEN enrolled 201 WM patients with a confirmed *MYD88* mutation, and 28 patients with wildtype *MYD88*. WM patients with *MYD88* muta...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Two trials: acalabrutinib in CLL Next Article
Deep responses in R/R CLL with venetoclax monotherapy »
Table of Contents: EHA 2020
Plasma Cell Dyscrasias
Bench-to-Bedside Science from the Presidential Symposium
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.